Antiacetylcholinesterase drugs
Neurotoxic venom effects can appear within a very short time following bites of numerous elapid species, several viper and other species.
The currently available antivenoms are not very effective with regard to their neurotoxin-neutralising activity.
For that reason alternative treatments that act in a timely and efficacious manner are required. Low molecular weight chemical inhibitors of neurotoxic PLA2 such as the selective sPLA2 inhibitor Varespladib have shown some promising activity against pre-synaptic snake neurotoxins and developments must be closely followed-up.
Endotracheal intubation and artificial respiration are reliable methods that are successful even if they need to be continued for days or even weeks.
Acetylcholinesterase inhibitors can be used in certain situations at least as adjunctive therapy. Their efficacy depends on the location of activity of the neurotoxins of a snake species and has been proven in clinical studies for some snake species, in particular for those species with postsynaptically active venoms (e.g. Naja philippinensis).
"Anticholinesterase drugs may produce a rapid, useful improvement in neuromuscular transmission in patients envenomed by some species of Asian and African cobras, death adders (Acanthophis species), some coral snakes (Micrurus species) and kraits" (Warrell 2023, citing Watt et al. 1986).
Tensilon test and treatment with acetylcholinesterase inhibitors
Warrell (2023), Watt et al. (1986)
Guidelines for the Management of Snakebites, WHO Regional Office SE Asia
| Diagnostic and treatment steps | Procedure | Comments |
|
Baseline observations and measurements |
Assessment:
|
The baseline observations and measurements are made against which to assess the effectiveness of the cholinesterase inhibitors. |
| Tensilon test |
Atropine sulphate i.v.: 0.6 mg (adults),
followed by
_______ Alternatively:
_______ Alternatively:
|
Indication: Some species of Asian and African cobras, death adders (Acanthophis species), some coral snakes (Micrurus species) and kraits" (Warrell 2023, citing Watt et al. 1986) or in the absence of evidence that points towards one of the culprits above, all patients with neurological signs of envenoming can be given a trial. However, this should not delay antivenom treatment or endotracheal intubation.
|
| Observation |
Observation of signs of improved neuromuscular transmission. Ptosis may disappearand ventilator capacity (peak flow, FEV-1 or maximum expiratory pressure) may improve. 10-20 minutes (Tensilon, edrophonium)
|
Assessment against the baseline observations and measurements. |
| Patients with a convincingly positive response | ||
| Long-acting anticholinesterase inhibitors |
Maintainance on neostigmine methylsulphate, 0.5–2.5 mg every 1–3 hours up to 10 mg/24 hours maximum for adults or 0.01–0.04 mg/kg every 2–4 hours for children, by intramuscular, intravenous or subcutaneous injection. _______ Alternatively:
_______ To block muscarinic effects: Atropine sulphate s.c. 15 µg/kg BW 4-hourly.
Adult patients able to swallow tablets may be maintained on
|
Indication: Improvement of neurological signs of envenoming under the Tensilon (edrophonium) test or altrenative tests (see above).
Dose adjustment: Titration according to the effect. Adverse reactions: Among other reactions, acetylcholinesterase inhibitors may cause cramping abdominal pain, which can be controlled with atropine. An overdose of acetylcholinesterase inhibitors can lead to a cholinergic crisis with progressive muscle weakness and respiratory paralysis. |